Your browser doesn't support javascript.
loading
ABSTRACT
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myeloid Cells / Intercellular Signaling Peptides and Proteins / Chemotherapy-Induced Febrile Neutropenia / Antineoplastic Agents Type of study: Etiology_studies / Guideline / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Natl Compr Canc Netw Year: 2017 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myeloid Cells / Intercellular Signaling Peptides and Proteins / Chemotherapy-Induced Febrile Neutropenia / Antineoplastic Agents Type of study: Etiology_studies / Guideline / Incidence_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Natl Compr Canc Netw Year: 2017 Document type: Article